Steven M. Rowe, M.D.
The mission of the Clinical and Translational Core is to bring state-of-the-art technology for patient orientated research to the cystic fibrosis program on our campus.
The transition of experimental interventions toward preclinical testing and ultimate clinical trials requires examination of efficacy and toxicity in human cells and tissues. Human primary nasal airway epithelial cells and bronchial airway epithelial cells (from bronchoscopy or other surgical remnant tissues) are provided by the Core for this purpose. The Core also includes expertise in the nasal potential difference measurement, an important endpoint in cystic fibrosis clinical trials, and a means to understand pathogenesis of cystic fibrosis and other metabolic diseases. Recently, the Core also initiated studies of pulmonary tissue physiology utilizing optical coherence tomography (OCT). These clinical assays help bridge the gap between preclinical animal studies and clinical trials and contribute to therapeutic development in the CF Research Center.
The Core was established in 1999 as a result of an award from the National Institute of Diabetes and Digestive and Kidney Diseases. Core users are typically associated with the Cystic Fibrosis Research Center, but there is no limitation on who may access the Core.
Core Director: Steven M. Rowe, M.D.
Cystic Fibrosis (CF) Clinical and Translational Core